Appili Therapeutics, Inc., a Halifax, Nova Scotia, Canada-based anti-infective drug development company, raised $2.15m in financing.
The round included further investments from current investors, including Innovacorp and new investors, including institutional support.
The company intends to use the proceeds to advance:
– its lead product candidate, a taste-masked antibiotic designed to treat anaerobic infections like Clostridium difficile, into clinical trials;
– a novel class of antibiotics targeting drug-resistant Gram-negative bacteria; and
– opportunities to add anti-infective programs to its pipeline.
Led by Kevin Sullivan, CEO, Appili Therapeutics is dedicated to identifying, acquiring and advancing novel therapeutics for infectious disease. The company has two anti-infective programs, ATI-1501 and ATI-1503, in its pipeline. ATI-1501, a taste-masked treatment for anaerobic infections, has been granted orphan drug status by the FDA. Appili plans to take ATI-1501 into clinical trials in 2017. Its second product, ATI-1503, is a novel antibiotic with broad potential to treat deadly Gram-negative infections such as Klebsiella pneumoniae.